{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T13:44:26Z","timestamp":1787406266397,"version":"build-2736575974"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Low-dose vaginal estrogen (VE) is a safe and effective treatment for genitourinary syndrome of menopause (GSM). The frequency of VE prescribing for GSM is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate VE prescriptions among women with GSM and to identify clinical phenotypes associated with VE claims.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This is a retrospective, population-based cohort study of a 20% random sample of Medicare fee-for-service beneficiaries enrolled in Parts A, B, and D from 2006 to 2018. Women aged 66 years and older with a diagnosis indicative of GSM were included. Exclusion criteria included diagnoses of breast and\/or endometrial cancer within 6 months of GSM diagnosis. Data analysis was performed from October 2023 to June 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Diagnosis indicative of GSM.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the proportion of women with a VE prescription claim (cream, ring, or tablet) during the follow-up period, from first GSM diagnosis to the end of Medicare enrollment or the study period. To quantify associations between patient characteristics and the likelihood of VE claims, univariable and multivariable logistic regression analyses were conducted.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 1\u202f838\u202f732 women with at least 1 GSM-related diagnosis were identified (median [IQR] age, 74 [69-81] years; median [IQR] follow-up, 8 [4-10] years). VE prescriptions were filled by 165\u202f530 women (9.0%) at a median (IQR) of 15 (2-46) months after diagnosis. Older women (adjusted odds ratio [aOR] for &amp;gt;86 years vs 66-70 years, 0.59; 95% CI, 0.58-0.60) and those with higher Charlson Comorbidity Index scores (aOR for score \u22655 vs 0, 0.67; 95% CI, 0.66-0.69) were less likely to have a VE claim. When comparing GSM symptom groups, women with recurrent urinary tract infections were least likely to have a VE claim (aOR vs local sexual symptoms, 0.54; 95% CI, 0.46-0.64). Women with vulvovaginal symptoms (aOR, 2.70; 95% CI, 2.45-2.97) and GSM multimorbidity (aOR, 15.91; 95% CI, 14.41-17.57) were most likely to have a VE claim.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this large cohort study, 9.0% of female Medicare beneficiaries with a diagnosis indicative of GSM filled a VE prescription. Younger and healthier beneficiaries and those with GSM multimorbidity were more likely to fill a VE prescription. The majority of patients with GSM symptoms, including dyspareunia, vulvovaginal atrophy, and recurrent urinary tract infections, did not fill a VE prescription. Improving patient and practitioner education, revising the diagnostic code schema to capture the full breadth of symptoms, and validating GSM clinical phenotypes will help facilitate care and enhance our understanding of symptoms in research studies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.49822","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:00:35Z","timestamp":1765900835000},"page":"e2549822","source":"Crossref","is-referenced-by-count":4,"title":["Vaginal Estrogen Utilization Among Medicare Beneficiaries With Genitourinary Syndrome of Menopause"],"prefix":"10.1001","volume":"8","author":[{"given":"Kelsey","family":"Gallo","sequence":"first","affiliation":[{"name":"Endeavor Health, Glenview, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyuan Amy","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Burton","sequence":"additional","affiliation":[{"name":"Department of Urology, City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Kamdar","sequence":"additional","affiliation":[{"name":"Center for Population Health Sciences, Stanford University, Stanford, California"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor"},{"name":"Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekene A.","family":"Enemchukwu","sequence":"additional","affiliation":[{"name":"Department of Urology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"10","key":"zoi251337r1","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society.","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"issue":"6","key":"zoi251337r2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/GME.0000000000001752","article-title":"Genitourinary syndrome of menopause: a systematic review on prevalence and treatment.","volume":"28","author":"Mili","year":"2021","journal-title":"Menopause"},{"issue":"5","key":"zoi251337r3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jama.2022.24140","article-title":"Management of menopausal symptoms: a review.","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"zoi251337r4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/GME.0000000000000281","article-title":"Day-to-day impact of vaginal aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women.","volume":"22","author":"Huang","year":"2015","journal-title":"Menopause"},{"issue":"2","key":"zoi251337r5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.6118\/jmm.2015.21.2.65","article-title":"The recent review of the genitourinary syndrome of menopause.","volume":"21","author":"Kim","year":"2015","journal-title":"J Menopausal Med"},{"issue":"3","key":"zoi251337r6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jsxm.2017.01.011","article-title":"The Women\u2019s EMPOWER Survey: women\u2019s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate.","volume":"14","author":"Krychman","year":"2017","journal-title":"J Sex Med"},{"issue":"9","key":"zoi251337r7","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.","volume":"27","author":"The NAMS 2020 GSM Position Statement Editorial Panel","year":"2020","journal-title":"Menopause"},{"issue":"1","key":"zoi251337r8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women\u2019s Health Initiative Observational Study.","volume":"25","author":"Crandall","year":"2018","journal-title":"Menopause"},{"issue":"6","key":"zoi251337r9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/GME.0000000000001054","article-title":"Trends in oral and vaginally administered estrogen use among US women 50 years of age or older with commercial health insurance.","volume":"25","author":"Weissfeld","year":"2018","journal-title":"Menopause"},{"issue":"1","key":"zoi251337r10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.291.1.47","article-title":"National use of postmenopausal hormone therapy: annual trends and response to recent evidence.","volume":"291","author":"Hersh","year":"2004","journal-title":"JAMA"},{"issue":"11","key":"zoi251337r11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJM199309093291102","article-title":"A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.","volume":"329","author":"Raz","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi251337r12","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S0002-9378(99)70597-1","article-title":"A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women.","volume":"180","author":"Eriksen","year":"1999","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"zoi251337r13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0020-7292(03)00200-5","article-title":"Local estrogen treatment in patients with urogenital symptoms.","volume":"82","author":"Simunic","year":"2003","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"zoi251337r14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/AOG.0000000000000526","article-title":"Vaginal estrogen for genitourinary syndrome of menopause: a systematic review.","volume":"124","author":"Rahn","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"3","key":"zoi251337r15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/JU.0000000000004589","article-title":"The AUA\/SUFU\/AUGS guideline on genitourinary syndrome of menopause.","volume":"214","author":"Kaufman","year":"2025","journal-title":"J Urol"},{"issue":"2","key":"zoi251337r16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels.","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric"},{"issue":"1","key":"zoi251337r22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/MLR.0000000000001216","article-title":"Validity of race and ethnicity codes in Medicare administrative data compared with gold-standard self-reported race collected during routine home health care visits.","volume":"58","author":"Jarr\u00edn","year":"2020","journal-title":"Med Care"},{"issue":"5","key":"zoi251337r23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/ije\/29.5.891","article-title":"Use of comorbidity scores for control of confounding in studies using administrative databases.","volume":"29","author":"Schneeweiss","year":"2000","journal-title":"Int J Epidemiol"},{"issue":"5","key":"zoi251337r25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1447-0756.2001.tb01266.x","article-title":"The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study.","volume":"27","author":"Manonai","year":"2001","journal-title":"J Obstet Gynaecol Res"},{"key":"zoi251337r26","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/0378-5122(95)00963-9","article-title":"Clinical trial of the estradiol vaginal ring in the U.S.","volume":"22","author":"Nachtigall","year":"1995","journal-title":"Maturitas"},{"issue":"9","key":"zoi251337r27","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.3128","article-title":"Menopausal hormone therapy use among postmenopausal women.","volume":"5","author":"Yang","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"4","key":"zoi251337r28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/gme.0b013e3181f43404","article-title":"Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009.","volume":"18","author":"Tsai","year":"2011","journal-title":"Menopause"},{"issue":"1","key":"zoi251337r29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/SPV.0000000000001504","article-title":"Vaginal estrogen prescribing and cost trends among Medicare part D beneficiaries.","volume":"31","author":"Tabakin","year":"2025","journal-title":"Urogynecology (Phila)"},{"issue":"3","key":"zoi251337r30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"zoi251337r31","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/GME.0000000000001282","article-title":"Menopausal hormone therapy trends before versus after 2002: impact of the Women\u2019s Health Initiative Study Results.","volume":"26","author":"Crawford","year":"2018","journal-title":"Menopause"},{"issue":"4","key":"zoi251337r32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/GME.0000000000000786","article-title":"The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.","volume":"24","author":"Constantine","year":"2017","journal-title":"Menopause"},{"issue":"4","key":"zoi251337r33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/gme.0b013e3181a48c4e","article-title":"Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally.","volume":"16","author":"Bachmann","year":"2009","journal-title":"Menopause"},{"issue":"4","key":"zoi251337r34","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/AOG.0b013e3181f386bb","article-title":"Endometrial safety of ultra-low-dose estradiol vaginal tablets.","volume":"116","author":"Simon","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"1","key":"zoi251337r35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1001\/jamaoncol.2023.4508","article-title":"Vaginal estrogen therapy use and survival in females with breast cancer.","volume":"10","author":"McVicker","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi251337r36","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/AOG.0000000000005294","article-title":"Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer.","volume":"142","author":"Agrawal","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"10","key":"zoi251337r37","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study.","volume":"114","author":"Cold","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"zoi251337r38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/ijgc-2019-001034","article-title":"Vaginal estrogen use for genitourinary symptoms in women with a history of uterine, cervical, or ovarian carcinoma.","volume":"30","author":"Chambers","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"zoi251337r39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","article-title":"Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynaecological Oncology Group study.","volume":"24","author":"Barakat","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi251337r40","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society.","volume":"29","author":"The North American Menopause Society Advisory Panel","year":"2022","journal-title":"Menopause"},{"key":"zoi251337r17","unstructured":"Stanford Center for Population Health Sciences. Medicare 20% [2006-2018] enrollment\/summary (MBSF) (version 1.0). 2021. Accessed November 10, 2025. https:\/\/stanford.redivis.com\/datasets\/e5h4-34n5ngp4r?v=1.0"},{"key":"zoi251337r18","unstructured":"Stanford Center for Population Health Sciences. Medicare 20% [2006-2018] MedPAR (version 1.0). 2021. Accessed November 10, 2025. https:\/\/stanford.redivis.com\/datasets\/bbsj-1sm6nv96h?v=1.0"},{"key":"zoi251337r19","unstructured":"Stanford Center for Population Health Sciences. Medicare 20% [2006-2018] Part D (version 3.0). 2023. Accessed November 10, 2025. https:\/\/stanford.redivis.com\/datasets\/g0qz-3zw17g9s5?v=3.0"},{"key":"zoi251337r20","unstructured":"Stanford Center for Population Health Sciences. Medicare 20% [2006-2018] carrier (version 1.0). 2021. Accessed November 10, 2025. https:\/\/stanford.redivis.com\/datasets\/0de4-fnmm4jzm2?v=1.0"},{"key":"zoi251337r21","unstructured":"Stanford Center for Population Health Sciences. Medicare 20% [2006-2018] outpatient (version 1.0). 2021. Accessed November 10, 2025. https:\/\/stanford.redivis.com\/datasets\/x40p-es5f323mb?v=1.0"},{"key":"zoi251337r24","unstructured":"Congressional Budget Office. Dual-eligible beneficiaries of Medicare and Medicaid: characteristics, health care spending, and evolving policies. June 6, 2013. Accessed March 23, 2025. https:\/\/www.cbo.gov\/publication\/44308"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842843\/gallo_2025_oi_251337_1765293627.4748.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:00:37Z","timestamp":1765900837000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.49822","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}